Molecular pathology and its relevance to thyroid FNA

David Poller; Sharon Glaysher

doi:10.1111/cyt.12492

Molecular pathology and its relevance to thyroid FNA

David Poller, Sharon Glaysher

Research output: Contribution to journal › Literature review › peer-review

308 Downloads (Pure)

Abstract

This review summarises molecular pathological techniques applicable to thyroid FNA. The molecular pathology of thyroid tumours is now fairly well understood. Molecular methods may be used as a rule-in test for diagnosis of malignancy in thyroid nodules e.g. BRAF V600E point mutation, use of a 7 gene mutational panel (BRAF V600E, RAS genes, RET/PTC or PAX8/PPARG rearrangement), or as a comprehensive multigene next-generation sequencing panel e.g. ThyroSeq v2. Molecular methods can also be applied as rule-out tests for malignancy in thyroid nodules e.g. Afirma or ThyroSeq v2 or as markers of prognosis e.g. TERT promoter mutation or other gene mutations including BRAF V600E, TP53 & AKT1 and as tests for newly defined tumour entities such as NIFTP, or as a molecular marker(s) for targeted therapies. This review describes practical examples of molecular techniques as applied to thyroid FNA in routine clinical practice.

Original language	English
Pages (from-to)	475-481
Number of pages	7
Journal	Cytopathology
Volume	28
Issue number	6
Early online date	22 Nov 2017
DOIs	https://doi.org/10.1111/cyt.12492
Publication status	Published - 1 Dec 2017

Keywords

diagnosis
fine-needle aspiration
molecular
neoplasms
pathology
thyroid

Access to Document

10.1111/cyt.12492

Molecular_Pathology_in_thyroid_FNA_Final
This is the peer reviewed version of the following article: Poller DN, Glaysher S. Molecular pathology and thyroid FNA. Cytopathology. 2017;28:475–481, which has been published in final form at DOI:10.1111/cyt.12492. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
Accepted author manuscript (Post-print), 791 KB

Cite this

@article{1dfdb07833aa4747a0f57012555584fe,

title = "Molecular pathology and its relevance to thyroid FNA",

abstract = "This review summarises molecular pathological techniques applicable to thyroid FNA. The molecular pathology of thyroid tumours is now fairly well understood. Molecular methods may be used as a rule-in test for diagnosis of malignancy in thyroid nodules e.g. BRAF V600E point mutation, use of a 7 gene mutational panel (BRAF V600E, RAS genes, RET/PTC or PAX8/PPARG rearrangement), or as a comprehensive multigene next-generation sequencing panel e.g. ThyroSeq v2. Molecular methods can also be applied as rule-out tests for malignancy in thyroid nodules e.g. Afirma or ThyroSeq v2 or as markers of prognosis e.g. TERT promoter mutation or other gene mutations including BRAF V600E, TP53 & AKT1 and as tests for newly defined tumour entities such as NIFTP, or as a molecular marker(s) for targeted therapies. This review describes practical examples of molecular techniques as applied to thyroid FNA in routine clinical practice.",

keywords = "diagnosis, fine-needle aspiration, molecular, neoplasms, pathology, thyroid",

author = "David Poller and Sharon Glaysher",

year = "2017",

month = dec,

day = "1",

doi = "10.1111/cyt.12492",

language = "English",

volume = "28",

pages = "475--481",

journal = "Cytopathology",

issn = "0956-5507",

publisher = "Wiley",

number = "6",

}

TY - JOUR

T1 - Molecular pathology and its relevance to thyroid FNA

AU - Poller, David

AU - Glaysher, Sharon

PY - 2017/12/1

Y1 - 2017/12/1

N2 - This review summarises molecular pathological techniques applicable to thyroid FNA. The molecular pathology of thyroid tumours is now fairly well understood. Molecular methods may be used as a rule-in test for diagnosis of malignancy in thyroid nodules e.g. BRAF V600E point mutation, use of a 7 gene mutational panel (BRAF V600E, RAS genes, RET/PTC or PAX8/PPARG rearrangement), or as a comprehensive multigene next-generation sequencing panel e.g. ThyroSeq v2. Molecular methods can also be applied as rule-out tests for malignancy in thyroid nodules e.g. Afirma or ThyroSeq v2 or as markers of prognosis e.g. TERT promoter mutation or other gene mutations including BRAF V600E, TP53 & AKT1 and as tests for newly defined tumour entities such as NIFTP, or as a molecular marker(s) for targeted therapies. This review describes practical examples of molecular techniques as applied to thyroid FNA in routine clinical practice.

AB - This review summarises molecular pathological techniques applicable to thyroid FNA. The molecular pathology of thyroid tumours is now fairly well understood. Molecular methods may be used as a rule-in test for diagnosis of malignancy in thyroid nodules e.g. BRAF V600E point mutation, use of a 7 gene mutational panel (BRAF V600E, RAS genes, RET/PTC or PAX8/PPARG rearrangement), or as a comprehensive multigene next-generation sequencing panel e.g. ThyroSeq v2. Molecular methods can also be applied as rule-out tests for malignancy in thyroid nodules e.g. Afirma or ThyroSeq v2 or as markers of prognosis e.g. TERT promoter mutation or other gene mutations including BRAF V600E, TP53 & AKT1 and as tests for newly defined tumour entities such as NIFTP, or as a molecular marker(s) for targeted therapies. This review describes practical examples of molecular techniques as applied to thyroid FNA in routine clinical practice.

KW - diagnosis

KW - fine-needle aspiration

KW - molecular

KW - neoplasms

KW - pathology

KW - thyroid

U2 - 10.1111/cyt.12492

DO - 10.1111/cyt.12492

M3 - Literature review

SN - 0956-5507

VL - 28

SP - 475

EP - 481

JO - Cytopathology

JF - Cytopathology

IS - 6

ER -

Molecular pathology and its relevance to thyroid FNA

Abstract

Keywords

Access to Document

Fingerprint

Cite this